Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial
Sign Up to like & getrecommendations! Published in 2017 at "PLoS Pathogens"
DOI: 10.1371/journal.ppat.1006182
Abstract: The canary pox vector and gp120 vaccine (ALVAC-HIV and AIDSVAX B/E gp120) in the RV144 HIV-1 vaccine trial conferred an estimated 31% vaccine efficacy. Although the vaccine Env AE.A244 gp120 is antigenic for the unmutated… read more here.
Keywords: trial; hiv; rv144; vaccine ... See more keywords